NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board<
15 Jun 2021

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting<
14 Jun 2021

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting<
14 Jun 2021

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

The results of the 90-day in vivo study were reported during an oral presentation entitled "Design Optimization of the CorWave Membrane LVAD."
OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function<
11 Jun 2021

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

OxThera AB, announces completion of its pivotal Phase 3 study and reports top line results.
Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors<
08 Jun 2021

Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors

Dr. Srivastava is currently the Chief Financial and Strategy Officer at eGenesis.
Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal<
03 Jun 2021

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Published results show efficacy in both adrenomyeloneuropathy (AMN) and cerebral ALD (cALD) related models.
Ysios Capital closes its third fund at €216 million ($260 million)<
26 May 2021

Ysios Capital closes its third fund at €216 million ($260 million)

To invest in up to 15 companies in Europe and the US, with eight investments already made alongside top US and European investors.
AELIX Therapeutics appoints Dr Melanie Rolli as CEO<
18 May 2021

AELIX Therapeutics appoints Dr Melanie Rolli as CEO

Dr Rolli will support the company’s vision of positioning HTI vaccines for future functional cure strategies.
SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting<
11 May 2021

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting<
10 May 2021

Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting

Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.